RXi Pharmaceuticals granted patent for fibrosis treatment technology RXi Pharmaceuticals has been granted a patent by the USPTO on its unique self-delivering RNAi compounds, for the treatment of fibrosis. The patent covers the use of sd-rxRNAs targeting CTGF, including RXI‑109, for the treatment of fibrotic disorders. The patent will expire in 2029.
News For RXII From The Last 14 Days
Check below for free stories on RXII the last two weeks.